
Base editing strategies employing combinations of cytosine base editors and guide RNAs can efficiently convert CAG to CAA in the huntingtin gene without generating significant indels, off-target edits, or transcriptome alterations, demonstrating their feasibility and specificity as a potential therapeutic approach for Huntington's disease.


coremsg

An expanded CAG repeat in the huntingtin gene ( HTT ) causes Huntington’s disease (HD). Since the length of uninterrupted CAG repeat, not polyglutamine, determines the age-at-onset in HD, base editing strategies to convert CAG to CAA are anticipated to delay onset by shortening the uninterrupted CAG repeat. Here, we developed base editing strategies to convert CAG in the repeat to CAA and determined their molecular outcomes and effects on relevant disease phenotypes. Base editing strategies employing combinations of cytosine base editors and gRNAs efficiently converted CAG to CAA at various sites in the CAG repeat without generating significant indels, off-target edits, or transcriptome alterations, demonstrating their feasibility and specificity. Candidate BE strategies converted CAG to CAA on both expanded and non-expanded CAG repeats without altering HTT mRNA and protein levels. In addition, somatic CAG repeat expansion, which is the major disease driver in HD, was significantly decreased by a candidate BE strategy treatment in HD knock-in mice carrying canonical CAG repeats. Notably, CAG repeat expansion was abolished entirely in HD knock-in mice carrying CAA-interrupted repeats, supporting the therapeutic potential of CAG-to-CAA conversion base editing strategies in HD and potentially other repeat expansion disorders.

### Competing Interest Statement

V.C.W. was a founding scientific advisory board member with financial interest in Triplet Therapeutics Inc. Her financial interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. V.C.W. is a scientific advisory board member of LoQus23 Therapeutics Ltd. and has provided paid consulting services to Acadia Pharmaceuticals Inc., Alnylam Inc., Biogen Inc. and Passage Bio. V.C.W. has received research support from Pfizer Inc.B.P.K is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital and is a scientific advisory board member of Acrigen Biosciences, Life Edit Therapeutics, and Prime Medicine. J-ML consults for Life Edit Therapeutics and serves in the advisory board of GenEdit Inc.

*   HD
    :   Huntington’s disease; huntingtin, HTT 
    Q
    :   glutamine
    CR
    :   canonical repeat
    LI
    :   loss of interruption
    DI
    :   duplicated interruption
    BE
    :   base editing
    CBE
    :   cytosine base editor
    PAM
    :   protospacer adjacent motif
    gRNA
    :   guide
    RNA
    :   iPSC, induced pluripotent stem cell
    EV
    :   empty vector.

Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease

efficient-base-editing-strategies-to-convert-cag-to-caa-repeats-and-diminish-the-disease-causing-mutation-in-huntington-s-disease


Efficient Base Editing Strategies to Convert CAG to CAA Repeats and Diminish the Disease-Causing Mutation in Huntington's Disease
